Curriculum Vitae For:

Michael Henry Frankel, M.D.

Practice Information	Gastroenterology Associates of Cleveland, Inc. 3700 Park East Drive, Suite 100 Beachwood, Ohio 44122
Office Phone **Office Fax**	216-593-7700 216-593-7192
Place of Birth	Cleveland, Ohio

Education

1965 - 1968	Cleveland Heights High School Honors: National Honor Society
1968 – 1972	University of Pittsburgh, B.S. Biology & Philosophy (Double Major) Honors: Magna Cum Laude, Phi Beta Kappa, Alpha Epsilon Delta (Pre-Medicine Honorary) - Deans List 1969, 1970, 1971, 1972
1972 – 1975	Ohio State University College of Medicine, Degree: M.D. Honors: Cum Laude – M.D. Degree completed in 3 years Honors in Medicine, Pediatrics, OB-GYN, Gastroenterology and Hematology
1975 – 1976	Intern – Straight Medicine, Washington University-Barnes Hospital, St. Louis, Missouri
1976 – 1977	Junior Assistant Resident in Medicine, Washington University - Barnes Hospital, St. Louis, Missouri
1977 – 1978	Senior Assistant Resident in Medicine, Washington University - Barnes Hospital, St. Louis, Missouri
1978 – 1980	Fellow in Gastroenterology, Case Western Reserve University, Combined University Hospitals and Cleveland VA Hospital Program Cleveland, Ohio

Honors

Guide to Americas Top Physicians Magazine 2003, 2009 and 2010	Named as one of the top gastroenterologists In the United States
Northern Ohio Live Magazine April 2005	Judged as top physician in Cuyahoga County in gastroenterology by over 3,000 Northeast Ohio doctors
Patient's Choice Award 2008, 2010	Selected by patients as one of Ohio's favorite physicians.
U.S News & World Report America's Best Hospitals 2003 Edition	Chief of the Division of Gastroenterology at Hillcrest Hospital. Ranked number 48 of of nation's Best Digestive Hospitals
U.S. News & World Report America's Best Hospitals 2009 Edition	Chief of the Division of Gastroenterology at Hillcrest Hospital. Ranked number 41 of the nation's Best Digestive Health Hospitals
Angie's List 2010	Angie's List selected healthcare provider – more positive reviews that any other gastroenterologist in Northeast Ohio

Work Experience	1980 - Present	Gastroenterology Associates of Cleveland, Inc. – Private Practice
Credentials	American Board of Internal Medicine – Board Certified Internal Medicine, September 13, 1978, # 67968	
	Board Certified – Gastroenterology, September 10, 1981, # 67968	
	Licensed in State of Ohio, 35.042247	
	Investigator Training for Medical Research – Certified July 2003 Western Institutional Review Board (WIRB)	
Academic Appointments	1975 - 1978	Assistant in Medicine- Washington University, St. Louis, Missouri
	1978 – 1980	Teaching Fellow – Case Western Reserve University School of Medicine
	1980- Present	Clinical Instructor – Case Western Reserve University School of Medicine
Medical Staff Activities	1994 - Present	Chief, Division of Gastroenterology, Hillcrest Hospital Cleveland Clinic Health Systems (CCHS), Mayfield Heights, Ohio
	1991 – Present	Medical Executive Committee Member
	1991 – Present	Chairman, Bylaws Committee, Hillcrest Hospital, Mayfield Heights, Ohio
	1988 – Present	Hospital Medical Staff Section Representative (OMSS) from Hillcrest Hospital to Ohio State Medical Association and American Medical Association
	1982 -1992	Chairman, Hyperalimentation Committee, Hillcrest Hospital
	1987 – 1995	Treasurer, Medical Staff, Hillcrest Hospital, Mayfield Heights, Ohio
	2005 – 2007	Chief of Staff- Elect, Medical Staff, Hillcrest Hospital, Mayfield Heights, Ohio
	2007 – 2009	Chief of Staff, Hillcrest Hospital, Mayfield Heights, Ohio
	2007 – 2009	Hillcrest Hospital Representative, Cleveland Clinic Health System Medical Operations Committee
	2007 – 2009	Member, Cleveland Clinic Health System Regional Leadership Council
	2009 – Present	Member, Cleveland Clinic Health System Medical Executive Council
	2009 – Present	Chair, Medical Staff Policy Committee of the Cleveland Clinic Medical Executive Council
Hospital Affiliations	1980 – Present	Hillcrest Hospital, Cleveland Clinic Health System
	2001 – Present	Marymount Hospital, Cleveland Clinic Health System

Professional Affiliations

American Society of Internal Medicine

Ohio State Medical Association

1988 – Present	Delegate to Annual Convention
1980 - 2004	OMSS Steering Committee
1992 - 2004	Secretary of OMSS Committee
1993	Reference Committee American Medical Association Academy of Medicine of Cleveland

Academy of Medicine of Cleveland

1988 - 1992	Chairman Young Physicians Section
1989 – 1992	Board of Directors
1990 – 1992	Executive Committee, Board of Directors
1991 – 1992	Vice President

Presentations and Publications

Presented to the Annual Meeting of American Gastroenterology Association, Salt Lake City, Utah. May 21, 1980. ***Independence of Sodium Transport from Chloride in Rabbit ileum Brush Border Membranes***

Presented to the Annual convention of American College of Gastroenterology, Toronto, Canada. October 13, 1980. ***An Evaluation of the Efficacy of Nasogastric Suction Treatment in Alcoholic Pancreatitis***

Frankel, M.H., Hopfer, V., ***Independence of Sodium Transport from Chloride in Rabbit Ileum Brush Border Membranes***, Gastroenterology 1980, 78:1167

Fuller RK, Loveland JP, Frankel MH, ***An Evaluation of the Efficacy of Nasogastric Suction Treatment in Alcoholic Pancreatitis***, American Journal of Gastroenterology, May 1981 75(5):349-53

Symposium Chairman:	Organized and presented: ***Nutrition in the Hospitalized Patient*** Hillcrest Hospital, Mayfield Heights, Ohio October 12, 1983 for 8 Category 1, CME credit hours

Appointments

Guest member of Editorial Board of the Medical Journal Gastroenterology chosen for expert opinion on papers submitted for publication. Special Acknowledgment published in Gastroenterology 1980; 79:1364

Clinical Research

- Multicenter Randomized, Double Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GRxxxxx in Combination with Clarithromycin Compared to GRxxxxx, Clarithromycin, and Placebo in Patient with Duodenal Ulcer.

- Multicenter Randomized, Double Blind, Placebo-Controlled Evaluation of Healing and Relapse Rates Following Oral GRxxxxx in Combination with Clarithromycin Compared to GRxxxxx, Clarithromycin, and Placebo in Patient with Gastric Ulcer.

- Double Blind, Randomized, Placebo-Controlled Study of The Safety and Efficacy of Three Dose Regimens of Oral XXXXX in the Treatment of Ulcerative Colitis.

- Twelve week-randomized, double blind, Placebo controlled, Multicenter Study of GRxxxxx in Female Subjects with Irritable Bowel Syndrome (IB.S.)

- Intron A & Ribavirin for Treatment of Patients with Interferon Refractory or Interferon-Relapsed Chronic Hepatitis C.

- Intron A & Ribavirin for Treatment of Patients with Chronic Hepatitis C, not previously treated with Intron A or Ribavirin.

- Double Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Efficacy and Safety of XXX in Non-Constipated Patients with Established Irritable Bowel Syndrome, ADDENDUM 1: An Open Labeled, Multi-Center Study to Investigate the Long Term Safety of XXX in Non-Constipated Patients with Established Irritable Bowel Syndrome

- Prospective, Randomized, Double-Blind, 3-arm Study to Compare the Efficacy and Safety of Celecoxib vs. Placebo in Reducing the Occurrence of New Adenomatous Polyps in the Colo-Rectum at Year 1, Year 3 and after Endoscopic Polypectomy

- A Clinical Study to Determine the Safety of Rxxxxxx in Subjects with Crohn's Disease

- TREAT Registry for Crohn's patients

- A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of XXX 2 mg BID and 5 mg BID Given Orally vs. Placebo in Patients with Chronic Constipation

- Prevention of Sporadic Colorectal Adenoma's with XXX

- Multi-Center, Open-Label, Safety Study of Oral XXX for the Treatment of Occasional Constipation

- Study of the Safety and Efficacy of XXX Treatment to Reduce the Growth of Sporadic Adenomatous Colorectal Polyps at Year One in Subjects with Intermediate Risk of Developing Adenomatous Polyps and Colorectal Cancer

- A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of 2 mg TID of XXX over 12 Weeks Followed by a 4-week Re-randomized Treatment Period in Diarrhea-Predominant Irritable Bowel Syndrome Subjects

- A Phase III 48-Week Open-Label Safety Study of Oral XX-XXXX for the Treatment of Occasional Constipation

- A Phase III, multi-national, multi-centre, double-blind, placebo-controlled, parallel group, 26 week study to assess the safety and efficacy of the humanised anti-TN PEG conjugate, XXXXXX, 400 mg, (dosed at Weeks 0, 2, 4 then 4-weekly to Week 24), in the treatment of patients with active Crohn's disease

- A Phase III, multi-national, multi-centre, open label, 52 week safety study to assess the safety of chronic therapy with the humanised anti-TNF PEG conjugate XXXXXX 400 mg sc, (dosed 4-weekly to Week 48), in the treatment of patients with active Crohn's disease who have previously completed studies XXXX-031 or XXXX-032

- A Phase III, multi-national, multi-centre, open label, 52 week safety study to assess the safety of re-exposure after a variable interval and subsequent chronic therapy with the humanised anti-TNF PEG conjugate XXXXXX 400 mg sc (Dosed at weeks 0, 2 and 4 then 4-weekly to Week 48), in the treatment of patients with active Crohn's disease who have previously been withdrawn from study XXXXXX-031 or XXXXXX-032 due to an exacerbation of Crohn's disease

- Irritable Bowel Syndrome Longitudinal Outcomes Study (ILOS)

- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody XXXXXXXX for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease who Have Lost Response or are Intolerant to Infliximab

- A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody XXXXX to Evaluate the Long-term Safety and Tolerability of Repeated Administration of XXXXXX in Subjects with Crohn's Disease

- A Phase 3 Study to Evaluate the Efficacy and Safety of XXX-XXX (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)

- A Phase 3 Study to Evaluate the Efficacy and Safety of XXX-XXXXX (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on healing of Erosive Esophagitis"

- A Phase 3 Study to Evaluate the Safety and Efficacy of XXX-XXXX (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis

- A Phase 3, Open-Label Study to Assess the Long-Term Safety of XXX-XXXX (60 mg QD and 90 mg QD)

- Multi-center, Randomized, Double-blind, Placebo-Controlled Trial of XXXX Tablets in the Treatment of Mild to Moderate Active Crohn's Disease in Adults

- Multi-center, Randomized, Blinded, Placebo Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous XXX-XX in Patients with Iron Deficiency Anemia

- A 12-Week, Multi-center, Double-Blind, Randomized Efficacy and Safety Study of XXXXXXXXXXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome

- An Open-Label Safety Study of XXXXXXXX for Constipation-Predominant Irritable Bowel Syndrome

- A Multi-center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody XXXXXXXXX in Patients with Moderate to Severe Crohn's Disease with Previous Exposure to Infliximab

- Qualitative Study of Patients with Gastroesophageal Reflux Disease

- A Multicenter, Randomized, Double-blind, Placebo-controlled study of the Human Anti-TNF Monoclonal Antibody XXXXXXXXXX for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis

- A phase IV multi-center, open-label study to assess clinical recurrence related to compliance with treatment with XXX mesalamine 2.4g/day given once daily for the maintenance of quiescent ulcerative colitis.

- A 5 year registry study of XXXXX in subjects with moderately to severely active Crohn's disease

- A phase 2B, multi-center, randomized, double-blind, placebo controlled, dose ranging study comparing the efficacy, safety, and pharmacokinetics of intravenous infusions of XXX-XXX vs. placebo in subjects with moderately to severely active Crohn's disease.